How do you define "low-volume" intermediate risk prostate cancer that is appropriate for brachytherapy alone?  

Specifically, what criteria do you use to quantify "low-volume" prostate cancer?  What other criteria do you consider when defining low volume intermediate risk prostate cancer that can be considered for bracthy monotherapy? 



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Academic Institution